<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Morinaga Milk Industry 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=20755></link><description><![CDATA[Morinaga Milk Industry 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 16:42:20 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><language>ko-KR</language><item><title><![CDATA[모리나가 유업, 자체 개발 프로바이오틱스에 대한 미 FDA의 비반대 의견서 취득]]></title><link>https://www.newswire.co.kr/newsRead.php?no=721297</link><description><![CDATA[도쿄--(Business Wire/뉴스와이어)--일본 유제품 분야 2위 기업인 모리나가(Morinaga) 유업(도쿄증시 종목코드: 2264)은 자체 개발 프로바이오틱 균주(probiotic strain)인 비피도박테리움 브레베(bifidobacterium breve) M-16V의 식품 및 분유 사용에 대해, 미 식약청(U.S. Food and Drug Administration, FDA)이 ‘GRAS(일반적으로 안전하다고 인정) 비반대 의견서(Letters of No Objection)’를 발행했다고 5...]]></description><pubDate>Wed, 06 Nov 2013 02:00:00 +0900</pubDate></item><item><title><![CDATA[Morinaga Milk Industry Co., Ltd. Receives U.S. FDA Letters of No Objection for its Proprietary Probiotic]]></title><link>https://www.newswire.co.kr/newsRead.php?no=721298</link><description><![CDATA[TOKYO--(Business Wire/Korea Newswire)--Morinaga Milk Industry Co., Ltd.(TOKYO:2264), the second largest dairy product company in Japan, today announced that the U.S. Food and Drug Administration (“FDA”) has issued Generally Recognized as Safe (GRAS) Letters of No Objection for Morinaga’s proprietary probiotic strain, Bifidobacterium breve M-16V for food applications and infant formul...]]></description><pubDate>Wed, 06 Nov 2013 02:00:00 +0900</pubDate></item></channel></rss>